Meta-Analysis of Randomized Trials on First Line and Adjunctive Levetiracetam (Q37868362)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21515509%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

0 references

1 reference

title

Meta-analysis of randomized trials on first line and adjunctive levetiracetam (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21515509%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Meta-Analysis of Randomized Trials on First Line and Adjunctive Levetiracetam (English)

1 reference

10.1017/S0317167100011902

DOI

https://api.crossref.org/works/10.1017/S0317167100011902

30 November 2024

Benjamin W Y Lo

0 references

Elie A Akl

object named as

Elie A Akl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21515509%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Draga Jichici

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21515509%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Hmwe H. Kyu

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21515509

30 November 2024

Adrian M. Upton

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21515509

30 November 2024

Maureen O. Meade

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21515509

30 November 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21515509

30 November 2024

publication date

1 May 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21515509%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

May 2011

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21515509

full work available at URL

30 November 2024

https://www.cambridge.org/core/services/aop-cambridge-core/content/view/77EF4213BD7792CB222DD2D23B5CE35D/S0317167100011902a.pdf/div-class-title-meta-analysis-of-randomized-trials-on-first-line-and-adjunctive-levetiracetam-div.pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21515509

https://www.cambridge.org/core/services/aop-cambridge-core/content/view/S0317167100011902

30 November 2024

1 reference

10.1017/S0317167100011902

DOI

https://api.crossref.org/works/10.1017/S0317167100011902

Canadian Journal of Neurological Sciences

30 November 2024

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21515509%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21515509%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21515509%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

page(s)

475-486

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21515509%20AND%20SRC:MED&resulttype=core&format=json

Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures

29 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011902

7 January 2021

A systematic review of the safety profile of levetiracetam: a new antiepileptic drug.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011902

7 January 2021

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011902

7 January 2021

A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011902

7 January 2021

Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011902

7 January 2021

Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011902

7 January 2021

Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011902

7 January 2021

Efficacy and safety of levetiracetam (3,000 mg/Day) as an adjunctive therapy in Chinese patients with refractory partial seizures.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011902

7 January 2021

Seizure‐free Days Observed in Randomized Placebo‐controlled Add‐on Trials with Levetiracetam in Partial Epilepsy

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011902

7 January 2021

Efficacy and safety of levetiracetam (up to 2000 mg/day) in Taiwanese patients with refractory partial seizures: a multicenter, randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011902

7 January 2021

Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011902

7 January 2021

Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011902

7 January 2021

Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011902

7 January 2021

Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011902

7 January 2021

Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011902

7 January 2021

The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011902

7 January 2021

Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011902

7 January 2021

Levetiracetam versus phenytoin for seizure prophylaxis in severe traumatic brain injury

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011902

7 January 2021

A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011902

7 January 2021

Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011902

7 January 2021

An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011902

7 January 2021

Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100011902

7 January 2021

10.1017/S0317167100011902

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21515509%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21515509%20AND%20SRC:MED&resulttype=core&format=json